Teplizumab induces persistent changes in the antigen‐specific repertoire in individuals at‐risk for type 1 diabetes

Teplizumab, a FcR non-binding anti-CD3 mAb, is approved to delay progression of type 1 diabetes (T1D) at-risk patients. Previous investigations described the immediate effects of the 14-day treatment, but longer-term effects of the drug remain unknown.